Catégorie : Substances psychédéliques et therapeutique

Ketamine for Depression Faces Its Biggest Test Yet , John Watson, 04/04/2019

Ketamine for Depression Faces Its Biggest Test Yet John Watson https://www.medscape.com/viewarticle/910994?nlid=129178_425&src=WNL_mdplsfeat_190409_mscpedit_psyc&uac=292598PZ&spon=12&impID=1932155&faf=1 April 04, 2019 One of the more unexpected stories from this past decade of psychiatric research has been the journey of ketamine from illicit drug to a promising therapy for treatment-resistant depression. Yet, even as its reputation has been burnished by accounts of patients experiencing dramatic responses to short-term therapy, ketamine was noticeably lacking in large-scale trials necessary to shift it further still, from an experimental treatment to an established intervention. In 2017, investigators sought to address this gap by initiating the ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression (ELEKT-D) trial.[1] Sponsored by [...]

Lire la suite

Ketamine a Panacea for Resistant Depression? Not So Fast, Experts Say, Nancy A. Melville , April 04, 2019

Ketamine a Panacea for Resistant Depression? Not So Fast, Experts Say Nancy A. Melville April 04, 2019 https://www.medscape.com/viewarticle/911378#vp_3   CHICAGO — Ketamine's rapid antidepressant effects and its recent approval by the US Food and Drug Administration (FDA) has clinicians and patients alike buzzing with excitement. However, for some experts, this excitement only serves to heighten concerns about the many unknowns and potential long-term side effects of the drug, which began its long history as an anesthetic. Here, at the Anxiety and Depression Association of American (ADAA) 2019 Conference, experts debated the drug's merits and potential pitfalls. "These are exciting times and I think ketamine has opened a new era," Carlos [...]

Lire la suite

Dans la Silicon Valley, le retour des drogues psychédéliques, Les Echo, Elsa Conesa, 4 avril 2019

Dans la Silicon Valley, le retour des drogues psychédéliques Cinquante ans après le Summer of love, les ingénieurs et programmeurs de la Silicon Valley ont renoué avec les drogues psychédéliques, censées accroître la créativité et la performance. Les employeurs ferment les yeux, voire les encouragent. Par Elsa CONESA Publié le 04/04 à 06h00 https://www.lesechos.fr/tech-medias/hightech/dans-la-silicon-valley-le-retour-des-drogues-psychedeliques-1006461   Tous les matins, c'est le même rituel. « Je me lève, je bois un thé vert, je prends ma dose, puis je médite un peu. Sous la douche, déjà, je commence à sentir les bénéfices, j'ai plein d'idées qui apparaissent. » Lové dans un fauteuil de l'hôtel Rosewood Sand Hill, le QG officieux [...]

Lire la suite

Dark Classics in chemical Neuroscience : Lysergic Acid Diethylamide (LSD), David E. Nichols, 2018

Dark Classics in chemical Neuroscience : Lysergic Acid Diethylamide (LSD), David E. Nichols, ACS Chemical Neuroscience, 2018, 9, 10, 2331-2334. doi: 10.1021/acschemneuro.8b00043. Abstract : LSD is one of the most potent psychoactive agents known, producing dramatic alterations of consciousness after submilligram (≥20 g) oral doses. Following the accidental discovery of its potent psychoactive effects in 1943, it was supplied by Sandoz Laboratories as an experimental drug that might be useful as an adjunct for psychotherapy, or to give psychiatrists insight into the mental processes in their patients. The finding of serotonin in the mammalian brain in 1953, and its structural resemblance to LSD, quickly led [...]

Lire la suite

Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study, Rafael F. Sanchez et al., 2016

Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study. Rafael F. Sanchez, F. de Lima Osorio, R.G. Dos Santos, L.R. Macedo, J.P. Maia-de-Oliveira, L. Wichert-Ana, D.B. de Araujo, J. Riba, J.A. Crippa, J.E. Hallak Journal of Clinical Psychopharmacology, 2016, 36, 1, 77-81. doi: 10.1097/JCP.0000000000000436. PMID : 26650973 Abstract Ayahuasca is an Amazonian botanical hallucinogenic brew which contains dimethyltryptamine, a 5-HT2A receptor agonist, and harmine, a monoamine-oxidase A inhibitor. Our group recently reported that ayahuasca administration was associated with fast-acting antidepressive effects in 6 depressive patients. The objective of the present work was to assess the antidepressive potentials of [...]

Lire la suite

État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21e siècle, Christian Sueur, 2017

État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21e siècle Christian Sueur Psychotropes, 2017/3 (Vol. 23), p. 125-163. DOI 10.3917/psyt.233.0125 https://www.cairn.info/revue-psychotropes-2017-3-page-125.htm   Résumé : L’utilisation thérapeutique des substances psychédéliques a été concomitante de la découverte du LSD et de la Mescaline après la Seconde Guerre mondiale. Ces utilisations thérapeutiques concernaient, à l’origine, essentiellement « l’accompagnement » des psychothérapies (thérapies psycholytiques), le traitement des addictions (alcool, puis opiacés) et, du fait de leurs capacités anxiolytiques et antidépressives, la prise en charge des troubles psychologiques post-traumatiques, les dépressions résistantes, les pathologies obsessionnelles et psychosomatiques (douleurs, migraines…) et l’accompagnement des fins [...]

Lire la suite

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer : a randomized controlled trial, Stephen Ross et al., 2016

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer : a randomized controlled trial ROSS S., BOSSIS A., GUSS J., AGIN-LIEBES G., MALONE T., COHEN B., MENNENGA S.E., BELSER A., KALLIONTZI K., BABB J., SU Z., CORBY P., SCHMIDT B.L. Journal of Psychopharmacology, 2016, 30, 12, 1165-1180 DOI: 10.1177/0269881116675512      jop.sagepub.com   Abstract Background : Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. Methods : In this double-blind, placebo-controlled, crossover trial, 29 patients [...]

Lire la suite

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer : A randomized double-blind trial, Roland D. Griffiths et al., 2016

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer : A randomized double-blind trial GRIFFITHS R.R., JOHNSON M.W., CARDUCCI M.A., UMBRICHT A., RICHARDS W.A., RICHARDS B.D., COSIMANO M.P., KLINEDINST M.A. Journal of Psychopharmacology, 2016, 30, 12, 1181–1197. DOI: 10.1177/0269881116675513       jop.sagepub.com   Abstract Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the effects of a very low (placebo-like) dose [...]

Lire la suite

Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression, Taylor Lyons, Robin L. Carhart-Harris, 2018

Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression LYONS T., CARHART-HARRIS R.L. Journal of Psychopharmacology, 2018, 32, 7, 811-819. Doi : 10.1177/0269881117748902   journals.sagepub.com/home/jop   Abstract Rationale : Previous research suggests that classical psychedelic compounds can induce lasting changes in personality traits, attitudes and beliefs in both healthy subjects and patient populations. Aim : Here we sought to investigate the effects of psilocybin on nature relatedness and libertarian authoritarian political perspective in patients with treatment-resistant depression (TRD). Methods : This open-label pilot study with a mixed-model design studied the effects of psilocybin on measures of nature relatedness and libertarian– authoritarian political perspective in patients with [...]

Lire la suite